Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Sanger sequencing service market was valued at USD 196 million in 2024. The market is projected to reach USD 194 million by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of -0.2% during the forecast period.
Sanger sequencing, also known as the chain-termination method, is a foundational technology for determining the nucleotide sequence of DNA. It remains the gold standard for accuracy and is extensively used for validating results from next-generation sequencing (NGS), sequencing singular genes, and verifying plasmid constructs. While the overall market is experiencing slight contraction due to the widespread adoption of high-throughput NGS, Sanger sequencing retains a critical niche because of its unequalled precision for smaller-scale projects.
Market dynamics are shaped by this technological transition. The demand is sustained by its indispensable role in applications requiring high confidence in results. For instance, the largest market share by application is held by research institutions at 28%, followed by biotech companies and universities. In terms of service types, sequencing of PCR products dominates the market with a 44% share, underscoring its role in routine molecular biology verification. Key players like Thermo Fisher Scientific, which holds approximately 16% of the market, continue to innovate with reagent kits and automated platforms to streamline the workflow, ensuring Sanger sequencing remains a vital and cost-effective tool in the genomics landscape.
Robust Demand in Biomedical Research and Diagnostics
The Sanger sequencing service market is primarily driven by its enduring role as the gold standard for validation in next-generation sequencing (NGS) workflows. Despite the rise of high-throughput methods, Sanger sequencing remains indispensable for confirming key genetic variants, mutations, and plasmid constructs due to its unparalleled accuracy and long read lengths. Its reliability makes it a critical tool in clinical diagnostics, particularly for applications requiring high confidence, such as oncogenic mutation detection and rare genetic disorder screening.
Growth in Pharmaceutical R&D and Quality Control
The pharmaceutical and biotechnology industries are significant consumers of Sanger sequencing services for drug discovery and development. It is extensively used for quality control of biologics, verifying cell lines, and ensuring the genetic stability of recombinant proteins. The increasing complexity of biologic drugs and regulatory requirements for stringent characterization continues to fuel demand for these precise sequencing services.
➤ Approximately 70% of clinical laboratories still utilize Sanger sequencing as a confirmatory test for NGS results, underscoring its critical role in ensuring diagnostic accuracy.
Furthermore, technological advancements, such as capillary electrophoresis systems with enhanced throughput and automation, have improved the efficiency and reduced the cost-per-sample for service providers. This has made Sanger sequencing more accessible for academic research and smaller biotech firms, sustaining market growth.
MARKET CHALLENGES
Competition from Next-Generation Sequencing Technologies
The most significant challenge for the Sanger sequencing service market is the dominant adoption of NGS for large-scale genomic studies. NGS offers massively parallel sequencing at a lower cost per base for whole genomes or exomes, making it the preferred choice for discovery-phase research. This has led to a gradual migration of certain applications away from Sanger sequencing, pressuring service providers to justify their value proposition based on accuracy rather than throughput.
Other Challenges
High Operational Costs and Limited Scalability
While cost-per-sample has decreased, the initial capital investment in advanced capillary sequencers and the recurring costs of reagents and maintenance remain substantial. The inherently lower throughput compared to NGS platforms also limits scalability for projects requiring the analysis of thousands of samples simultaneously.
Demand for Rapid Turnaround Times
The market faces increasing pressure to deliver faster results to meet the accelerating pace of research and clinical decision-making. Optimizing workflow efficiency from sample preparation to data analysis is a constant operational challenge for service providers.
Market Saturation in Mature Applications
A key restraint on market growth is the maturity of its core applications. Markets in North America and Europe are well-established, with growth rates stabilizing. While demand is consistent, the explosive growth phase has passed for routine applications like SNP validation and microbial identification, leading to a more competitive landscape focused on pricing and service quality rather than market expansion.
Price Sensitivity and Budget Constraints
Academic institutions and smaller diagnostic labs often operate on constrained budgets. As the cost of alternative technologies like targeted NGS panels continues to fall, customers become more price-sensitive. Service providers must constantly balance maintaining high-quality standards with competitive pricing, which can squeeze profit margins.
Expansion in Emerging Economies and Applied Markets
Significant growth opportunities exist in expanding access to Sanger sequencing services in emerging economies across Asia-Pacific and Latin America. As biotechnology and pharmaceutical investment grows in these regions, the demand for reliable, accurate sequencing for quality control and basic research is rising. Furthermore, applied markets such as agricultural biotechnology and forensic science present untapped potential for service providers.
Integration with Automation and Bioinformatics
The development of fully automated, high-throughput Sanger sequencing workflows integrated with sophisticated bioinformatics platforms represents a major opportunity. By offering turnkey solutions that minimize hands-on time and deliver rapid, easy-to-interpret results, service providers can differentiate themselves and capture value from clients lacking in-house expertise or infrastructure.
Finally, the increasing regulatory emphasis on data integrity and validation in clinical diagnostics and drug development ensures a sustained, long-term need for Sanger sequencing. Service providers that can offer GMP-compliant and CLIA-certified services are well-positioned to secure contracts with pharmaceutical companies and clinical laboratories.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
PCR Products maintains a dominant position as the leading segment, driven by their ubiquity in routine molecular biology workflows such as clone validation, SNP genotyping, and mutation detection. The critical need for high-fidelity verification of amplified DNA sequences underpins this sustained demand. Plasmid DNA sequencing follows as a crucial service, particularly for confirmatory sequencing in genetic engineering and biomanufacturing. The 'Others' category remains vital, encompassing niche but important applications like sequencing of small genomes or specialized vectors. |
| By Application |
|
Research Institutions form the cornerstone of the market, leveraging Sanger sequencing's gold-standard accuracy for foundational genomic research and exploratory studies. Biotech companies and pharmaceutical firms are also significant consumers, heavily relying on the technology for quality control, construct validation, and supporting regulatory submissions where unambiguous sequence data is non-negotiable. Universities and colleges utilize these services extensively for teaching and academic research. The application in hospitals and clinics, while growing for diagnostic confirmation, represents a specialized segment requiring stringent validation and accreditation. |
| By End User |
|
Academic & Research end users represent the largest and most established segment, characterized by high volume demand for reliable, cost-effective sequencing to support a wide array of basic and applied research projects. The Industrial & Commercial segment, including biotech and pharmaceutical companies, is a major driver of value, requiring high-throughput services with guaranteed turnaround times and strict data integrity to support product development. The Clinical & Diagnostic segment, while smaller, is highly specialized, demanding services that meet rigorous clinical laboratory standards for applications in genetic disease diagnosis and pathogen identification. |
| By Service Level |
|
Standard Sequencing is the most frequently requested service level, catering to the routine needs of academic and smaller industrial labs for single-pass sequencing and verification. High-Throughput Screening services are essential for industrial clients engaged in large-scale projects like mutagenesis screens or clone library validation, demanding efficiency and scalability. Custom & Specialized Services, such as long-read sequencing, difficult templates (e.g., high GC-content), or rapid turnaround for clinical samples, represent a high-value niche where service providers differentiate themselves through technical expertise and reliability. |
| By Sequencing Read Length |
|
Short-Read sequencing services are the most commonly utilized, perfectly suited for the vast majority of applications including PCR product verification, SNP confirmation, and small fragment analysis due to their cost-effectiveness and high accuracy. Medium-Read lengths are critical for applications requiring greater contiguous sequence information, such as sequencing larger genes or validating cloning junctions. Long-Read services, while more specialized and challenging, are indispensable for de novo sequencing initiatives, resolving complex genomic regions, and applications where maximizing contiguous data from a single read is paramount, representing a key area of technical capability for leading service providers. |
A Concentrated Market Led by Global Life Science Giants
The global Sanger sequencing service market is characterized by a relatively high level of concentration, with the top three producers collectively holding over 40% of the market share. Thermo Fisher Scientific stands as the undisputed leader, commanding approximately 16% of the global market. The company's dominance is underpinned by its extensive portfolio of genetic analysis instruments and reagents, integrated service offerings, and a vast global distribution and support network. Azenta Life Sciences and Eurofins Scientific are other major global players that compete effectively through their large-scale, high-throughput sequencing facilities and strong reputations for data quality and reliability, particularly serving pharmaceutical, biotechnology, and academic clients.
Beyond the market leaders, the landscape includes a diverse array of specialized and regional players that have carved out significant niches. Companies such as LGC Biosearch Technologies, GenScript Biotech, and QuintaraBio have established strong positions by offering tailored services, rapid turnaround times, and expertise in specific applications like plasmid sequencing or validation. The market also features numerous regional specialists, particularly in Asia, such as Tsingke Biotechnology, Guangzhou IGE Biotechnology, and SciGenom Labs, which cater to growing local demand. Other notable providers like Microsynth, Fasteris, and Nucleics compete on technological specialization and customer service, ensuring a dynamic and competitive environment for end-users in research institutions, biotech firms, and universities.
List of Key Sanger Sequencing Service Companies ProfiledThermo Fisher Scientific
Fasteris
QuintaraBio
Laragen
Microsynth
Nucleics
CeMIA
StarSEQ
Source BioScience
Guangzhou Life Technologies DaAn
SciGenom Labs
The global Sanger Sequencing Service market, valued at $196 million in 2024, is projected to reach $194 million by 2031, reflecting a compound annual growth rate (CAGR) of -0.2%. This nearly flat growth trajectory signals a market in a mature phase of its lifecycle. The primary factor influencing this trend is the increasing competition from advanced next-generation sequencing (NGS) technologies, which offer higher throughput capabilities. However, Sanger sequencing maintains a critical and stable niche. Despite its age, the Sanger method's benchmark accuracy for validating NGS results and its cost-effectiveness for low-to-medium throughput applications continue to ensure steady demand. Its widespread use in applications like plasmid validation, mutation confirmation, and small-scale targeted sequencing underpins its enduring market presence.
Other TrendsMarket Consolidation and Dominance by Key Players
The market is characterized by a consolidated competitive landscape, with the top three companies Thermo Fisher, Eurofins Scientific, and Azenta collectively holding over 40% of the market share. Thermo Fisher stands as the largest single producer, commanding 16% of the market. This concentration drives a trend towards service bundling and competitive pricing strategies. Smaller players are differentiating themselves by specializing in rapid turnaround times, niche applications, and providing value-added services such as extensive bioinformatics support and comprehensive data analysis to maintain competitiveness against the scale of the market leaders.
Application and Product Type Segmentation DynamicsAnalysis by product type reveals that sequencing PCR products is the dominant segment, holding 44% of the market share, followed by plasmid DNA. This reflects the extensive use of Sanger sequencing for confirmation and validation workflows in genetic research and biomanufacturing. In terms of applications, research institutions form the largest customer base with a 28% market share. The demand from biotech companies and universities is also significant, driven by foundational research, product development, and academic studies. This segmentation highlights the market's reliance on the academic and industrial research sectors, where the gold-standard accuracy of Sanger sequencing remains indispensable.
Regional Analysis: Sanger Sequencing Service MarketEurope
Europe represents a mature and highly significant market for Sanger sequencing services, characterized by strong national and pan-European research initiatives. Countries like Germany, the UK, and France are major contributors, with well-established infrastructure in both academic and commercial sectors. The market dynamics are influenced by collaborative projects such as those funded by the European Union's Horizon programmes, which promote genomic research and create centralized demand for sequencing services. A strong emphasis on data privacy and adherence to regulations like the In Vitro Diagnostic Regulation (IVDR) shapes service offerings, particularly for clinical applications. The presence of numerous sequencing core facilities within universities and research institutes provides a decentralized yet robust network of service providers, catering to a diverse range of scientific inquiries from biodiversity studies to medical genetics.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for Sanger sequencing services, fueled by rapidly expanding biotechnology sectors, increasing government investment in genomics, and a growing base of academic research. China, Japan, and India are key drivers, with China making particularly significant strides in building large-scale genomic research capabilities. While next-generation sequencing is growing rapidly, Sanger sequencing remains essential for validation and targeted applications, especially in clinical settings and agricultural biotechnology. The market is characterized by a mix of large international service providers establishing local presence and a burgeoning number of domestic companies offering cost-effective services. Growth is further propelled by the increasing outsourcing of research and development activities by multinational pharmaceutical companies to contract research organizations in the region.
South America
The Sanger sequencing service market in South America is emerging, with growth primarily concentrated in countries like Brazil and Argentina. The market is largely driven by academic and governmental research institutions focused on areas such as public health, agricultural genomics, and biodiversity. Funding constraints compared to North America or Europe can limit the scale of projects, but there is a consistent demand for reliable DNA sequencing for essential research. Service provision is often localized through university core facilities and a small number of specialized private labs. The market shows potential for growth as regional collaborations strengthen and investment in life sciences infrastructure gradually increases, though it remains a smaller segment of the global landscape.
Middle East & Africa
The Middle East and Africa region presents a developing market for Sanger sequencing services, with activity focused on specific hubs. In the Middle East, countries like Israel, Saudi Arabia, and the United Arab Emirates are investing in genomic medicine and research, creating demand for sequencing services, often for clinical and diagnostic purposes. In Africa, South Africa is the most established market, with research often centered on infectious diseases like HIV/AIDS and tuberculosis, as well as human population genetics. Across the region, the market is constrained by varying levels of research funding and infrastructure development. However, there is growing recognition of the importance of genomics, leading to gradual market expansion through international partnerships and local capacity-building initiatives.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets极
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide极 range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Sanger sequencing service market was valued at USD 196 million in 2024 and is expected to reach USD 194 million by 2031.
-> Key players include Thermo Fisher, Azenta, Eurofins Scientific, and LGC Biosearch Technologies, among others.
-> Key growth drivers include validation of next-generation sequencing results and demand for high-accuracy DNA sequencing.
-> North America holds a significant market share, while Asia shows growing adoption.
-> Emerging trends include automated workflows, reagent innovations, and continued niche applications in precision validation.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates